Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of pulmonary disease in cystic fibrosis.

@article{Ramalho2002FivePO,
  title={Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of pulmonary disease in cystic fibrosis.},
  author={Anabela S Ramalho and Sebastian Beck and Michelle J. Meyer and Deborah Penque and Garry R Cutting and Margarida D. Amaral},
  journal={American journal of respiratory cell and molecular biology},
  year={2002},
  volume={27 5},
  pages={
          619-27
        }
}
  • Anabela S Ramalho, Sebastian Beck, +3 authors Margarida D. Amaral
  • Published in
    American journal of…
     2002
  • Biology, Medicine
    • Estimates of the level of transcripts from the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) gene required to develop a CF phenotype range from 4-20% of normal. Due to the importance of obtaining reliable data on this issue for therapeutic strategies, we developed a novel polymerase chain reaction-based method to quantify CFTR transcripts and applied it to the analysis of nasal epithelium RNA of five patients with CF and the 3272-26A>G/F508del genotype. We calculated that 8.2… CONTINUE READING
    View PDF
    94 Citations
    40 Cite Background
    3 Cite Results

    Figures, Tables, and Topics from this paper.

    Figures and Tables

    Explore Further: Topics Discussed in This Paper

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 94 CITATIONS, ESTIMATED 62% COVERAGE

    The Experimentally Obtained Functional Impact Assessments of 5' Splice Site GT>GC Variants Differ Markedly from Those Predicted

    Correlating Cystic Fibrosis Transmembrane Conductance Regulator Function with Clinical Features to Inform Precision Treatment of Cystic Fibrosis

    Cystic fibrosis in the era of effective treatment: Informing targeted therapy and influencing reproductive decision-making

    Dual strategies to correct abnormal ion transports in cystic fibrosis using construct therapy

    VIEW 1 EXCERPT
    CITES BACKGROUND

    The effect of premature termination codon mutations on CFTR mRNA abundance in human nasal epithelium and intestinal organoids: a basis for read‐through therapies in cystic fibrosis

    VIEW 1 EXCERPT
    CITES RESULTS

    The experimentally obtained functional impact assessments of GT>GC 5’ splice site variants differ markedly from those predicted

    VIEW 1 EXCERPT
    CITES BACKGROUND

    Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors

    CFTR and Cystic Fibrosis: From Structure to Function

    VIEW 1 EXCERPT
    CITES BACKGROUND

    CFTR dysfunction in cystic fibrosis and chronic obstructive pulmonary disease.

    VIEW 1 EXCERPT
    CITES BACKGROUND

    Chitosan in Non-Viral Gene Delivery: Role of Structure, Characterization Methods, and Insights in Cancer and Rare Diseases Therapies

    VIEW 1 EXCERPT
    CITES BACKGROUND

    FILTER CITATIONS BY YEAR

    2003
    2020

    References

    Publications referenced by this paper.
    SHOWING 1-9 OF 9 REFERENCES

    Cystic fibrosis patients with the 3272nary and pancreatic phenotype but with male infertility

    • H. Cuppens, J. Lavinha
    • 2001

    Cystic fibrosis patients with the 3272-26A-->G mutation have mild disease, leaky alternative mRNA splicing, and CFTR protein at the cell membrane.

    Identification of a splice site mutation in the cystathionine beta-synthase gene resulting in variable and novel splicing defects of pre-mRNA.

    Transcript analysis of CFTR nonsense

    • Tümmler, J. Schmidtke
    • 1995

    Down-regulation of cystic fibrosis gene mRNA transcript levels and induction of the cystic fibrosis chloride secretory phenotype in epithelial cells by phorbol ester.

    [The polymerase chain reaction].

    Quantitation of mRNA by the polymerase chain reaction.

    The cystic fibrosis gene is found.

    Enzymatic gene amplification: qualitative and quantitative methods for detecting proviral DNA amplified in vitro.